Number of agents being developed to combat drug resistant bacteria is “alarmingly low,” warns reportBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2548 (Published 19 April 2013) Cite this as: BMJ 2013;346:f2548
- Michael McCarthy
Little progress is being made to develop new drugs to combat the growing threat of drug resistant bacteria, a new report from the Infectious Diseases Society of America has said.
In the report a society panel focused on systemic drugs for the treatment of multidrug resistant Gram negative bacilli, pathogens that are responsible for a substantial proportion of serious infections in US hospitals.1
In their review the authors were able to identify only seven new systemic antibiotics targeting drug resistant Gram negative bacilli that had reached phase II or III trials, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial